Azizul Haque1, Anudeep B Pant2. 1. One Medical Center Drive, Department of Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Lebanon, NH 03756, USA. 2. New Orleans East Hospital, 5620 Read Blvd, New Orleans, LA 70127, USA.
Abstract
The rapid spread of SARS-CoV-2, the new coronavirus (CoV), throughout the globe poses a daunting public health emergency. Different preventive efforts have been undertaken in response to this global health predicament; amongst them, vaccine development is at the forefront. Several sophisticated designs have been applied to create a vaccine against SARS-CoV-2, and 44 candidates have already entered clinical trials. At present, it is unclear which ones will meet the objectives of efficiency and safety, though several vaccines are gearing up to obtain emergency approval in the U.S. and Europe. This manuscript discusses the advantages and disadvantages of various vaccine platforms and evaluates the safety and efficacy of vaccines in advance stages. Once a vaccine is developed, the next challenge will be acquisition, deployment, and uptake. The present manuscript describes these challenges in detail and proposes solutions to the vast array of translational challenges. It is evident from the epidemiology of SARS-CoV-2 that the virus will remain a threat to everybody as long as the virus is still circulating in a few. We need affordable vaccines that are produced in sufficient quantity for use in every corner of the world.
The rapid spread of SARS-CoV-2, the n class="Species">new coronavirus (CoV), throughout the globe poses a daunting public health emergency. Different preventive efforts have been undertaken in response to this global health predicament; amongst them, vaccine development is at the forefront. Several sophisticated designs have been applied to create a vaccine against SARS-CoV-2, and 44 candidates have already entered clinical trials. At present, it is unclear which ones will meet the objectives of efficiency and safety, though several vaccines are gearing up to obtain emergency approval in the U.S. and Europe. This manuscript discusses the advantages and disadvantages of various vaccine platforms and evaluates the safety and efficacy of vaccines in advance stages. Once a vaccine is developed, the next challenge will be acquisition, deployment, and uptake. The present manuscript describes these challenges in detail and proposes solutions to the vast array of translational challenges. It is evident from the epidemiology of SARS-CoV-2 that the virus will remain a threat to everybody as long as the virus is still circulating in a few. We need affordable vaccines that are produced in sufficient quantity for use in every corner of the world.
Entities:
Keywords:
COVID-19 disease; pandemics; public health; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); trials; vaccines
Authors: Nina Le Bert; Anthony T Tan; Kamini Kunasegaran; Christine Y L Tham; Morteza Hafezi; Adeline Chia; Melissa Hui Yen Chng; Meiyin Lin; Nicole Tan; Martin Linster; Wan Ni Chia; Mark I-Cheng Chen; Lin-Fa Wang; Eng Eong Ooi; Shirin Kalimuddin; Paul Anantharajah Tambyah; Jenny Guek-Hong Low; Yee-Joo Tan; Antonio Bertoletti Journal: Nature Date: 2020-07-15 Impact factor: 49.962
Authors: Trevor R F Smith; Ami Patel; Stephanie Ramos; Dustin Elwood; Xizhou Zhu; Jian Yan; Ebony N Gary; Susanne N Walker; Katherine Schultheis; Mansi Purwar; Ziyang Xu; Jewell Walters; Pratik Bhojnagarwala; Maria Yang; Neethu Chokkalingam; Patrick Pezzoli; Elizabeth Parzych; Emma L Reuschel; Arthur Doan; Nicholas Tursi; Miguel Vasquez; Jihae Choi; Edgar Tello-Ruiz; Igor Maricic; Mamadou A Bah; Yuanhan Wu; Dinah Amante; Daniel H Park; Yaya Dia; Ali Raza Ali; Faraz I Zaidi; Alison Generotti; Kevin Y Kim; Timothy A Herring; Sophia Reeder; Viviane M Andrade; Karen Buttigieg; Gan Zhao; Jiun-Ming Wu; Dan Li; Linlin Bao; Jiangning Liu; Wei Deng; Chuan Qin; Ami Shah Brown; Makan Khoshnejad; Nianshuang Wang; Jacqueline Chu; Daniel Wrapp; Jason S McLellan; Kar Muthumani; Bin Wang; Miles W Carroll; J Joseph Kim; Jean Boyer; Daniel W Kulp; Laurent M P F Humeau; David B Weiner; Kate E Broderick Journal: Nat Commun Date: 2020-05-20 Impact factor: 14.919
Authors: Bette Korber; Will M Fischer; Sandrasegaram Gnanakaran; Hyejin Yoon; James Theiler; Werner Abfalterer; Nick Hengartner; Elena E Giorgi; Tanmoy Bhattacharya; Brian Foley; Kathryn M Hastie; Matthew D Parker; David G Partridge; Cariad M Evans; Timothy M Freeman; Thushan I de Silva; Charlene McDanal; Lautaro G Perez; Haili Tang; Alex Moon-Walker; Sean P Whelan; Celia C LaBranche; Erica O Saphire; David C Montefiori Journal: Cell Date: 2020-07-03 Impact factor: 66.850